{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T02:27:07Z","timestamp":1770431227085,"version":"3.49.0"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81860042"],"award-info":[{"award-number":["81860042"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma. While the R-CHOP regimen achieves a 70% 5-year survival rate, patients with refractory or relapsed disease face poor prognoses. Therefore, it is very important to search for markers related to curative effect and prognosis, and to explore new targeted therapies. Protein kinase C delta (PKC\u03b4), a serine\/threonine kinase involved in cell proliferation, growth, and cancer progression, has been proposed as a prognostic marker in solid tumors, but its role in DLBCL remains underexplored. This study aimed to validate PKC\u03b4 as a prognostic biomarker and investigate its mechanistic contributions to therapeutic resistance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Immunohistochemistry (IHC) was used to analyze the expression of PKC\u03b4 in 200 DLBCL tissues to validate the correlation between PKC\u03b4 and therapeutic efficacy as well as prognosis. Using the DB and RIVA cell lines to stably knock down the PRKCD gene, we explored the role of PKC\u03b4 in cell proliferation, cell cycle, apoptosis, chemoresistance, and related signaling pathways through CCK-8 assays, flow cytometry, RNA sequencing, and in vivo xenograft models in nude mice. Additionally, we evaluated the therapeutic efficacy of the multi-kinase inhibitor Rottlerin both in vitro and in vivo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>High PKC\u03b4 expression correlated with reduced 5-year progression-free survival and overall survival. Knockout of PKC\u03b4 repressed DLBCL cell proliferation, facilitated cell cycle arrest in the G2\/M phase, induced apoptosis in vitro, and inhibited tumor growth in vivo, and enhanced sensitivity to rituximab and chemotherapeutics. Similarly, inhibition with the multi-kinase inhibitor Rottlerin also impaired tumor growth and showed combinatory efficacy with rituximab. RNA-seq revealed 2,988 differentially expressed genes enriched in AKT, MAPK, and NF-\u03baB signaling pathways.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Our findings highlight PKC\u03b4 as a potential predictive biomarker and therapeutic target. However, due to the off-target effects of Rottlerin, the observed in vivo efficacy and synergistic effects of Rottlerin should be considered as preliminary pharmacological support for the concept of targeting PKC\u03b4.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1690426","type":"journal-article","created":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T13:26:41Z","timestamp":1770384401000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Research on the correlation and potential mechanism of PKC\u03b4 expression with efficacy and prognosis in diffuse large B-cell lymphoma"],"prefix":"10.3389","volume":"16","author":[{"given":"Xulu","family":"Zhao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanshan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aziguli","family":"Maihemaiti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abulikemujiang","family":"Adili","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shujuan","family":"Wen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26151","article-title":"2021 update on diffuse large B cell lymphoma: a review of current data and potential applications on risk stratification and management","volume":"96","author":"Susanibar-Adaniya","year":"2021","journal-title":"Am J Hematol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/s41408-021-00456-w","article-title":"Diffuse large B-cell lymphoma: new targets and novel therapies","volume":"11","author":"Cheson","year":"2021","journal-title":"Blood Cancer J"},{"key":"B3","doi-asserted-by":"publisher","first-page":"107924","DOI":"10.1016\/j.pharmthera","article-title":"Pharmacogenetics in diffuse large B-cell lymphoma treated with R-CHOP: Still an unmet challenge","volume":"229","author":"Lavacchi","year":"2022","journal-title":"Pharmacol Ther"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2016.1.366","article-title":"Diffuse large B-cell lymphoma: R-CHOP failure\u2014what to do","volume":"2016","author":"Coiffier","year":"2016","journal-title":"Hematology"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002982","article-title":"Long-term outcomes of R-CEOP show curative potential in patients with DLBCL and a contraindication to anthracyclines","volume":"5","author":"Moccia","year":"2021","journal-title":"Blood Adv"},{"key":"B6","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/S41568-020-00310-4","article-title":"Equivocal, explicit and emergent actions of PKC isoforms in cancer","volume":"21","author":"Parker","year":"2021","journal-title":"Nat Rev Cancer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s43018-022-00510-x","article-title":"Integrative multi-omics networks identify PKC\u03b4 and DNA-PK as master kinases of\u00a0glioblastoma subtypes and guide targeted cancer therapy","volume":"4","author":"Migliozzi","year":"2023","journal-title":"Nat Cancer"},{"key":"B8","doi-asserted-by":"publisher","first-page":"eabe4509","DOI":"10.1126\/scisignal.abe4509","article-title":"mTORC2 controls the activity of PKC and Akt by phosphorylating a conserved TOR interaction motif","volume":"14","author":"Baffi","year":"2021","journal-title":"Sci Signal"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-016-0323-0","article-title":"Protein kinase C \u03b4: a gatekeeper of immune homeostasis","volume":"36","author":"Salzer","year":"2016","journal-title":"J Clin Immunol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e20210501","DOI":"10.1084\/jem.20210501","article-title":"Impaired respiratory burst contributes to infections in PKC\u03b4-deficient patients","volume":"218","author":"Neehus","year":"2021","journal-title":"J Exp Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"eadd3231","DOI":"10.1126\/sciadv.add3231","article-title":"Protein kinase C delta regulates mononuclear phagocytes and hinders response to immunotherapy in cancer","volume":"9","author":"Chaib","year":"2023","journal-title":"Sci Adv"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.25358","article-title":"PKC\u03b4 Inhibition impairs mammary cancer proliferative capacity but selects cancer stem cells, involving autophagy","volume":"117","author":"Berardi","year":"2016","journal-title":"J Cell Biochem"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-021-01889-0","article-title":"PKC\u03b4-mediated SGLT1 upregulation confers the acquired resistance of NSCLC to EGFR TKIs","volume":"40","author":"Chen","year":"2021","journal-title":"Oncogene"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.0c01271","article-title":"Identification, structure\u2013activity relationships of marine-derived indolocarbazoles, and a dual PKC\u03b8\/\u03b4 Inhibitor with potent antipancreatic cancer efficacy","volume":"63","author":"Wang","year":"2020","journal-title":"J Med Chem"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14215425","article-title":"Protein kinase C (PKC) isozymes as diagnostic and prognostic biomarkers and therapeutic targets for cancer","volume":"14","author":"Kawano","year":"2022","journal-title":"Cancers"},{"key":"B16","volume-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"Sabattini","year":"2008"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn112152-20210516-00382","volume":"43","year":"2021","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199309303291402","article-title":"A predictive model for aggressive non-hodgkin\u2019s lymphoma","volume":"329","year":"1993","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13045-017-0391-5","article-title":"Klotho, an anti-aging gene, acts as a tumor suppressor and inhibitor of IGF-1R signaling in diffuse large B cell lymphoma","volume":"10","author":"Zhou","year":"2017","journal-title":"J Hematol Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/his.13270","article-title":"Clinicopathological characteristics of KIT and protein kinase C-\u03b4 expression in adenoid cystic carcinoma: comparison with chromophobe renal cell carcinoma and gastrointestinal stromal tumour","volume":"71","author":"Park","year":"2017","journal-title":"Histopathology"},{"key":"B21","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.ccell.2015.02.005","article-title":"A functional landscape of resistance to ALK inhibition in lung cancer","volume":"27","author":"Wilson","year":"2015","journal-title":"Cancer Cell"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2017.27","article-title":"Co-dependency of PKC\u03b4 and K-Ras: inverse association with cytotoxic drug sensitivity in KRAS mutant lung cancer","volume":"36","author":"Ohm","year":"2017","journal-title":"Oncogene"},{"key":"B23","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/j.ccell.2018.11.007","article-title":"Targeting PKC\u03b4 as a therapeutic strategy against heterogeneous mechanisms of EGFR inhibitor resistance in EGFR-mutant lung cancer","volume":"34","author":"Lee","year":"2018","journal-title":"Cancer Cell"},{"key":"B24","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1186\/s12906-015-0810-5","article-title":"Role of ellagic acid in regulation of apoptosis by modulating novel and atypical PKC in lymphoma bearing mice","volume":"15","author":"Mishra","year":"2015","journal-title":"BMC Complement Altern Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3390\/cells10050987","article-title":"Targeting cutaneous T-cell lymphoma cells by\u00a0ingenol mebutate (PEP005) correlates with PKC\u03b4 Activation, ROS induction as well as downregulation of XIAP and c-FLIP","volume":"10","author":"Sumarni","year":"2021","journal-title":"Cells"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2121-13-7","article-title":"PKC-\u03b4 mediates interferon-\u03b1-induced apoptosis through c-Jun NH2-terminal kinase activation","volume":"13","author":"Yanase","year":"2012","journal-title":"BMC Cell Biol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1186\/s12916-022-02670-0","article-title":"Tumor PKC\u03b4 instigates immune exclusion in EGFR-mutated non-small cell lung cancer","volume":"20","author":"Zuo","year":"2022","journal-title":"BMC Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.735183","article-title":"Suppression of EGFR\/PKC-\u03b4\/NF-\u03baB signaling associated with imipramine-inhibited progression of non-small cell lung cancer","volume":"11","author":"Yueh","year":"2021","journal-title":"Front Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.4c00213","article-title":"Evo312: an evodiamine analog and novel PKC\u03b2I inhibitor with potent antitumor activity in gemcitabine-resistant pancreatic cancer","volume":"67","author":"Bae","year":"2024","journal-title":"J Med Chem"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.217963","article-title":"The ALDH2-PKC delta-SHMT2 axis regulates cellular metabolic plasticity to promote leukemia stem cells self-renewal and evasion of chemotherapy in AML","volume":"632","author":"Hu","year":"2025","journal-title":"Cancer Lett"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.282789","article-title":"Ribosomal protein S3 mediates drug resistance of proteasome inhibitor: potential therapeutic application in multiple myeloma","volume":"109","author":"Chen","year":"2024","journal-title":"Haematol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21103527","article-title":"Suppression of PKC\u03b4\/NF-\u03baB signaling and apoptosis induction through extrinsic\/intrinsic pathways are associated magnolol-inhibited tumor progression in colorectal cancer in vitro and in vivo","volume":"21","author":"Su","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-15-0951","article-title":"Loss of PKC\u03b4 Induces prostate cancer resistance to paclitaxel through activation of wnt\/\u03b2-catenin pathway and mcl-1 accumulation","volume":"15","author":"Flores","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-010-0956-2","article-title":"Involvement of PKC delta (PKC\u03b4) in the resistance against different doxorubicin analogs","volume":"126","author":"D\u00edaz Bessone","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1042\/BST20140189","article-title":"The many hats of protein kinase C\u03b4: one enzyme with\u00a0many functions","volume":"42","author":"Qvit","year":"2014","journal-title":"Biochem Soc Trans"},{"key":"B36","doi-asserted-by":"publisher","first-page":"e70246","DOI":"10.1002\/ctm2.70246","article-title":"SH3GL1-activated FTH1 inhibits ferroptosis and confers doxorubicin resistance in diffuse large B-cell lymphoma","volume":"15","author":"Duan","year":"2025","journal-title":"Clin Transl Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1690426\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T13:26:42Z","timestamp":1770384402000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1690426\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,6]]},"references-count":36,"alternative-id":["10.3389\/fonc.2026.1690426"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1690426","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,6]]},"article-number":"1690426"}}